|
Phase III study shows Novartis drug Afinitor® more than doubles time without tumor growth
|
02 July 2010 |
|
FDA approves Tasigna® for newly diagnosed chronic myeloid leukemia patients
|
22 June 2010 |
|
FDA advisory committee recommends approval of Novartis investigational treatment FTY720
|
14 June 2010 |
|
Novartis announces extension of US regulatory priority review period for FTY720
|
28 May 2010 |
|
Ranibizumab significantly more effective than standard of care in treating vision loss due to DME
|
24 May 2010 |
|
Novartis healthcare portfolio generates strong growth in first quarter of 2010
|
27 April 2010 |
|
Sandoz to acquire Oriel Therapeutics, gaining rights to portfolio of respiratory products
|
20 April 2010 |
|
A potential first-in-class, once-daily oral therapy for relapsing forms of multiple sclerosis
|
14 April 2010 |
|
Novartis receives FDA approval of Menveo®
|
23 February 2010 |
|
Novartis gains exclusive rights to Debio 025
|
11 February 2010 |